Publications
226
Citations
7,027
Est. group size
~1
Recurring co-author estimate
Active years
37
Publishing since 1990
Typically publishes in teams of ~12 · 0% small-team papers (≤3 authors) · across 41 venues
- Cardiac Myosin Activation Enhances Contractility While Preserving Myocardial Energetics Compared With β-Adrenergic Stimulation
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy
JACC Heart Failure · 2025
- A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin
International Journal of Toxicology · 2025
- Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial
European Heart Journal · 2025
- Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2025
- A characterization of aficamten, a cardiac myosin inhibitor, in core battery safety pharmacology studies
Journal of Pharmacological and Toxicological Methods · 2025
- Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALS
Journal of Neuromuscular Diseases · 2025
- Hospitalizations as an outcome measure in COURAGE-ALS
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2025
- APOL1 Status of HIV-Positive Kidney Transplant Recipients and Its Impact on Survival: A Single-Centre UK Experience
American Journal of Transplantation · 2025
- Abstract Or301: Preclinical characterization of CK-4021586, a new class of cardiac myosin inhibitors, for the treatment of heart failure with preserved ejection fraction
Circulation Research · 2025
- Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALS
Utrecht University Repository (Utrecht University) · 2025
- Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy
Nature Cardiovascular Research · 2024
- Super-relaxed myosins contribute to respiratory muscle hibernation in mechanically ventilated patients
Science Translational Medicine · 2024
- Discovery of Nelutroctiv (CK-136), a Selective Cardiac Troponin Activator for the Treatment of Cardiovascular Diseases Associated with Reduced Cardiac Contractility
Journal of Medicinal Chemistry · 2024
- Pathogenic <i>TNNI1</i> variants disrupt sarcomere contractility resulting in hypo- and hypercontractile muscle disease
Science Translational Medicine · 2024
- Journal of the American College of Cardiology×29
- Circulation×17
- Journal of Cardiac Failure×14
- JACC Heart Failure×10
- Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration×7
- Stuart Kupfer
Medicine · University of Michigan
- Caroline Coats
Medicine · University of Michigan
- Anjali Owens
Medicine · University of Michigan
- Michael A. Fifer
Medicine · University of Michigan
- Martin S. Maron
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile